Cel-Sci offers a dose of transparency, but it doesn’t make its story credible

CHICAGO — I met Cel-Sci CEO Geert Kersten for the first time on Monday at the annual meeting of the American Society of Clinical Oncology. The company presented a poster describing the results of its Phase 3 study of the immunotherapy Multikine in patients with head and neck cancer.

Kersten introduced me to someone else as a “journalist,” which I appreciated because he usually describes me as an “aging blogger.” He was kind enough to walk me through the Multikine data, insisting the results from the study were overwhelmingly positive, showing a statistically significant survival benefit for patients treated with Multikine.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED


Adam Feuerstein

Source link